View clinical trials related to Fetal Aneuploidy.
Filter by:Whole blood samples will be collected from high-risk pregnant women to validate the clinical performance of the SEQureDx Trisomy 21 Test.
The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.
Can a combination of prenatal screening blood tests, early ultrasound, and a 3D ultrasound of the fetal face at approximately 20 weeks gestation identify fetuses with congenital anomalies and predict maternal and fetal complications?